# Adrian Mander

DART: Design and Analysis of Randomised Trials**Telephone number**: 01223 760728**Email Address**: adrian.mander@mrc-bsu.cam.ac.uk

## Person overview

Since 2009, Dr Adrian Mander has been the director of the MRC Biostatistics Unit Hub for Trials Methodology Research and co-leads the unit’s Design and Analysis of Randomised Trials (DART) research. Dr Mander is co-chair of the MRC Hub Network and was the founding lead of the Hub Network’s Adaptive Trials Working Group. Previously Dr Mander was the lead statistician of the MRC Human Nutrition Unit, a statistical manager at GlaxoSmithKline and his first post-doctoral position was in the London Schoool of Hygiene and Tropical Medicine. Dr Mander’s research interests are primarily in the area of adaptive clinical trial design using either Bayesian or Frequentist methods. His current focus is in the translation of novel designs into every day practice.

## BSU Research overview

Time and resources available for the development of new treatments are increasingly difficult to find, so there is a real need to demonstrate that studies offer value for money. For this reason, trials are increasingly being designed to give them the flexibility to adapt as the data emerges, and to be used to plan the extent and scope of the next phase of research. Adaptations include: varying the doses to find the optimal one for future trials; dropping ineffective treatments earlier; finding the best treatment amongst several; and deciding on the sample size of a trial using only limited information. We have a series of research areas that are tackling these issues using adaptive clinical trials. Recently we have developed novel trial designs that minimise the expected sample size and therefore the average costs of trials by using interim analyses whilst still maintaining good statistical practice of controlling the error probabilities. We are now extending our methods to tackle areas such as dual-agent dose escalation studies, dose finding trials and biomarker driven trial design. We are placing emphasis on the translational side of our work by disseminating our findings to clinical and statistical audiences, providing easy to use software and training the community to implement our methodology.

## Adaptive Clinical Trials research team

### Statisticians

- Graham Wheeler
- Sofia Villar
- James Howlett
- Julie Wych

### PhD students

## Selected Papers

**Grayling, M. and Mander, A.P.**(2015)

Do single-arm trials have a role in drug development plans incorporating randomised trials?*Pharm. Stat.***DOI: 10.1002/pst.1726**:**Mander, A.P. and Sweeting M.J**(2015)

A product of Independent beta probabilities dose escalation design for dual-agent Phase I trials.*Stat. Med.***34 (8)**: 1261-1276**Wason, J., Stetcher, L. and Mander, A.P.**(2014)

Correcting for multiple testing in multi-arm trials: Is it necessary and is it done?*Trials***15(1)**: 364-371**Bowden, J. and Mander, A.P**(2014)

A review and re-interpretation of a group-sequential approach to sample size re-estimation in two stage trials.*Pharm.Statistics***13(3)**: 163-72**Mander, A.P. and Thompson, S.G.**(2010)

Two-stage designs optimal under the alternative hypothesis for phase II cancer trials.*Contemporary Clinical***31(6)**: 572-578**Mander, A. P., Wason, J. M. S., Sweeting, M. J. & Thompson, S. G.**(2012)

Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis.*Pharmaceutical Statistics***11**: 91-96**Wason, J. M., Mander, A. P. & Thompson, S. G.**(2012)

Optimal multi-stage designs for randomised clinical trials with continuous outcomes.*Statistics in Medicine***31**: 301-312**Sweeting, M.J. & Mander, A.P.**(2012)

Escalation strategies for combination therapy phase I trials.*Pharmaceutical Statistics***11**: 258-266**Wason, J. M. S., Mander, A. P. & Eisen, T. G.**(2011)

Using continuous tumour shrinkage endpoints in two-stage phase II cancer trial designs.*European Journal of Cancer***47**: 983-989**Mander, A. P. & Thompson, S. G.**(2010)

Two-stage designs optimal under the alternative hypothesis for phase II cancer trials.*Contemporary Clinical Trials***31**: 572-578